Myriad Announces Publication of Variant Reclassification Study in the Journal of the American Medical AssociationNasdaqResults Show 25 Percent of All Reported Variants of Uncertain Significance Were Reclassified over a 10-Year Period. SALT LAKE CITY, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized ...and more »